Operating Expenses Changement Date
Acadia Pharmaceuticals USD 196.1M 73.38M 2023-12
Aceragen USD 23.08M 14.13M 2023-03
Agios Pharmaceuticals USD 113.38M 5.08M 2023-12
Alnylam Pharmaceuticals USD 556.12M 19.46M 2023-12
Amgen USD 6.93B 2.11B 2023-12
BioCryst Pharmaceuticals USD 98.66M 33.55M 2023-09
Biogen USD 2.03B 344.1M 2023-12
BioMarin Pharmaceutical USD 631.99M 76.32M 2023-12
Bluebird Bio USD 97.12M 4.93M 2023-09
Bristol-Myers Squibb USD 9.62B 984M 2023-12
Eli Lilly USD 6.97B 2.08B 2023-12
Exelixis USD 489.5M 97.5M 2023-09
Gilead Sciences USD 5.5B 1.08B 2023-12
Incyte USD 826.07M 121.75M 2023-12
Ionis Pharmaceuticals USD 303.83M 14.26M 2023-12
Lumos Pharma USD 8.94M 1.23M 2023-09
Merck USD 16.56B 6.35B 2023-12
Moderna USD 2.8B 1.04B 2023-12
Nektar Therapeutics USD 69.01M 2.09M 2023-09
Neurocrine Biosciences USD 357.6M 21.5M 2023-09
Pfizer USD 20.8B 4.62B 2023-12
PTC Therapeutics USD 438.79M 124.05M 2023-12
Regeneron Pharmaceuticals USD 2.46B 209.7M 2023-12
Sarepta Therapeutics USD 380.16M 87.4M 2023-09
Ultragenyx Pharmaceutical USD 249.44M 6.29M 2023-12
Vertex Pharmaceuticals USD 1.45B 21.4M 2023-09



Incyte Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2024.